Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amarin To Acquire Ester Neurosciences, Gain Clinical-Stage Neuromuscular Drug

This article was originally published in The Pink Sheet Daily

Executive Summary

Amarin CEO Stewart tells “The Pink Sheet” DAILY about the company’s partnering strategy for neurology and cardiovascular drugs.

You may also be interested in...

Amarin Plans Additional Phase III Trial For Miraxion To Support Huntington's NDA

London firm aims to substantiate the effectiveness of the neuroprotector in a genetic subgroup of Huntington's patients.

Pfizer Strengthens Therapeutic Vaccine Position With Coley Purchase

Pharma giant gains control over Coley’s Toll-like receptor patent estate and next-generation vaccine adjuvants with $164 million acquisition.

MoCRA Registrants Encouraged By Glimpse Into Cosmetics Direct Portal, But Apprehensions Remain

Jessica O’Connell, partner at Covington & Burling, is getting questions from clients about the electronic system the FDA plans to launch in coming weeks for cosmetics manufacturers to register facilities and list products as required by new cosmetics regulations. It remains to be seen how hard the 29 December 2023 deadline will be for companies to get their information submitted.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts